evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

336 questions · 354 findings · 32 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 71 · 20.1%GRADE not reported 33 · 9.3%Very low 70 · 19.8%Low 82 · 23.2%Moderate 75 · 21.2%High 23 · 6.5%

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Progression‐free survival (PSF) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower progression‐free survival (at 24 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant
1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Mortality within the longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower on‐study mortality (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Overall survival: Median length of · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab probably leads to lower overall survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical

Treament related mortality · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy with alemtuzumab showed no clear difference in treament related mortality compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (low certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical

Complete response · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy with alemtuzumab showed no clear difference in complete response rate compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (moderate certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Progression‐free survival · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab may leads to lower progression free survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Treatment related mortality · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in treatment related mortality compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Cytomegalovirus reactivation · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab leads to higher cytomegalovirus reactivation compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (high certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Complete response · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab may leads to higher complete response rate compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Infections (all grades) · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab may leads to higher infections (all grades) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Serious adverse events · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).

1 finding from 1 review